Our Company

1-10 of 24

A claims-based analysis of sickle cell disease: Prevalence, disease complications, and costs10 October 2019 - By Carol Bazell and Gabriela Dieguez and Christine Ferro and Harsha Mirchandani - Article

This research report uses real-world medical and pharmacy claims data for sickle cell disease patients covered either by commercial insurance or managed Medicaid to develop relevant diagnosis, utilization, and cost metrics by payer type.

Understanding the Part D spending dynamics of heart failure patients11 June 2019 - By Gabriela Dieguez and Amy Kwong and Jared Hirsch and Melissa A. Caplen - Article

This paper examines the Part D spending of Medicare patients with heart failure.

A claims-based analysis of secondary progressive multiple sclerosis (SPMS): Prevalence, demographics, and costs08 April 2019 - By Carol Bazell and Gabriela Dieguez and Christine Ferro - Article

This paper examines the prevalence, demographics, and healthcare cost of secondary progressive multiple sclerosis patients.

Can voluntary POS rebates work for Medicare Part D?12 February 2019 - By Jennifer Carioto and Gabriela Dieguez and Bruce S. Pyenson - Article

This report examines why Medicare Part D plans that share manufacturer rebates at the point of sale under a voluntary system will likely have a rather high premium relative to market averages.

Pulmonary arterial hypertension in the commercial population26 December 2018 - By Gabriela Dieguez and Michele M. Berrios and Mona Kelkar - Article

An analysis of over 900 people with endothelin receptor antagonist and/or Prostacyclin use to determine drug adherence, treatment patterns, healthcare spending, and comorbid conditions.

The cost burden of blood cancer care29 October 2018 - By David Rotter and Gabriela Dieguez and Christine Ferro - Article

This study identifies the total healthcare allowed spending and patient out-of-pocket costs from the year before diagnosis with a blood cancer through the three years after diagnosis.

Newly diagnosed hepatitis C in the U.S. commercially insured population before and after the 2012 implementation of expanded screening guidelines30 July 2018 - By Gabriela Dieguez and Bruce S. Pyenson and Christine Ferro - Article

This research compares the demographics, comorbidities, and medical costs of newly diagnosed patients and those who were previously diagnosed with HCV infection after the Centers for Disease Control and Prevention expanded its HCV testing recommendations to target adults born between 1945 and 1965.

Understanding the Part D spending dynamics of heart failure patients26 July 2018 - By Gabriela Dieguez and Harsha Mirchandani and Jared Hirsch - Article

Understanding pharmacy spending by heart failure patients requires an evaluation of the complex interactions between members, payers, manufacturers, and the government in Part D.

A primer on prescription drug rebates: Insights into why rebates are a target for reducing prices21 May 2018 - By Gabriela Dieguez and Maggie Alston and Samantha Tomicki - Article

This article explains the finances associated with pharmaceutical manufacturer rebates and their impact on health insurer coverage decisions.

The impact of California’s prescription drug cost-sharing cap27 March 2018 - By Gabriela Dieguez and Bruce S. Pyenson and Andrew Bochner - Article

This report analyzes the impact of the per-prescription cost-sharing cap for non-catastrophic plans on projected prescription drug spending across the California individual and small group markets.


  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman